{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:30:21Z","timestamp":1790641821709,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>The Molecular Microscope Diagnostic System (MMDx) may overcome histology shortcomings. Previous studies have simply examined discrepant findings but have not attempted to determine clinical endpoints. To measure performance, clinical outcomes are strongly required.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>This single-center cohort study described discrepancies between MMDx and histology from 51 kidney transplant recipients (KTRs) and analyzed 72 indication biopsies, including 21 follow-up biopsies. Clinical performance was assessed by a combined endpoint of graft failure, rejection on follow-up biopsy, de novo donor-specific antibody, and improvement of kidney allograft function upon antirejection treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>MMDx agreed in 33 (65%) and differed in 18 (35%) of 51 KTRs. Most discrepancies occurred in biopsies called no rejection by MMDx and rejection by histology (15\/24, 63%). In contrast, in biopsies called rejection by MMDx, 3 were classified as no rejection by histology (3\/27, 11%). Discrepant findings between MMDx and histology occurred following delayed graft function and MMDx from biopsies with a low percentage of cortex. Among 15 biopsies classified as no rejection by MMDx but rejection by histology, the clinical course suggested no rejection in 9 cases. Six KTRs reached the endpoint, showing predominant t \u2265 2 lesions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>The most often occurring discrepancy is rejection by histology but no rejection by MMDx. As more KTRs do not meet the combined endpoint for rejection, MMDx might be clinically useful in these discrepant cases. Although strong histological findings have priority in indicating the treatment, clinical implementation of MMDx could strengthen treatment strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000004284","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T04:00:36Z","timestamp":1663560036000},"page":"485-494","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":30,"title":["The Molecular Diagnosis Might Be Clinically Useful in Discrepant Kidney Allograft Biopsy Findings: An Analysis of Clinical Outcomes"],"prefix":"10.1097","volume":"107","author":[{"given":"Thomas","family":"Schachtner","sequence":"first","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich, Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seraina","family":"von Moos","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich, Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanna M.","family":"Kokkonen","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich, Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Helmchen","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Zurich, Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana","family":"Gaspert","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Zurich, Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Mackova","sequence":"additional","affiliation":[{"name":"Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip F.","family":"Halloran","sequence":"additional","affiliation":[{"name":"Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich, Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1523-1755.1999.00299.x","article-title":"The Banff 97 working classification of renal allograft pathology.","volume":"55","author":"Racusen","year":"1999","journal-title":"Kidney Int"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/TP.0000000000002366","article-title":"A 2018 reference guide to the banff classification of renal allograft pathology.","volume":"102","author":"Roufosse","year":"2018","journal-title":"Transplantation"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection.","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transplant"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/00000478-200306000-00012","article-title":"International variation in histologic grading is large, and persistent feedback does not improve reproducibility.","volume":"27","author":"Furness","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1046\/j.1523-1755.2001.00030.x","article-title":"International variation in the interpretation of renal transplant biopsies: report of the CERTPAP Project.","volume":"60","author":"Furness","year":"2001","journal-title":"Kidney Int"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nrneph.2016.85","article-title":"Molecular assessment of disease states in kidney transplant biopsy samples.","volume":"12","author":"Halloran","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1681\/ASN.2011090887","article-title":"Molecular phenotypes of acute kidney injury in kidney transplants.","volume":"23","author":"Famulski","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1172\/JCI41789","article-title":"A molecular classifier for predicting future graft loss in late kidney transplant biopsies.","volume":"120","author":"Einecke","year":"2010","journal-title":"J Clin Invest"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/ajt.15351","article-title":"Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers.","volume":"19","author":"Reeve","year":"2019","journal-title":"Am J Transplant"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/ajt.14233","article-title":"The effect of cortex\/medulla proportions on molecular diagnoses in kidney transplant biopsies: rejection and injury can be assessed in medulla.","volume":"17","author":"Madill-Thomsen","year":"2017","journal-title":"Am J Transplant"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"94197","DOI":"10.1172\/jci.insight.94197","article-title":"Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes.","volume":"2","author":"Reeve","year":"2017","journal-title":"JCI Insight"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1111\/ajt.14329","article-title":"Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX study.","volume":"17","author":"Halloran","year":"2017","journal-title":"Am J Transplant"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/ajt.15752","article-title":"Discrepancy analysis comparing molecular and histology diagnoses in kidney transplant biopsies.","volume":"20","author":"Madill-Thomsen","year":"2020","journal-title":"Am J Transplant"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/ajt.12079","article-title":"Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies.","volume":"13","author":"Reeve","year":"2013","journal-title":"Am J Transplant"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1097\/TP.0000000000003885","article-title":"The Use of molecular techniques to distinguish BK nephropathy from acute rejection: close but not quite.","volume":"105","author":"Pesavento","year":"2021","journal-title":"Transplantation"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1097\/TP.0000000000003884","article-title":"A 2-fold approach to polyoma virus (BK) nephropathy in kidney transplants: distinguishing direct virus effects from cognate T cell-mediated inflammation.","volume":"105","author":"Halloran","year":"2021","journal-title":"Transplantation"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1600-6143.2011.03784.x","article-title":"The nature of biopsies with \u201cborderline rejection\u201d and prospects for eliminating this category.","volume":"12","author":"de Freitas","year":"2012","journal-title":"Am J Transplant"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/TP.0000000000003838","article-title":"Correlation of donor-derived cell-free DNA with histology and molecular diagnoses of kidney transplant biopsies.","volume":"106","author":"Gupta","year":"2022","journal-title":"Transplantation"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1111\/ajt.15822","article-title":"High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury.","volume":"20","author":"Stites","year":"2020","journal-title":"Am J Transplant"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"788818","DOI":"10.3389\/fimmu.2022.788818","article-title":"High PIRCHE scores may allow risk stratification of borderline rejection in kidney transplant recipients.","volume":"13","author":"Lezoeva","year":"2022","journal-title":"Front Immunol"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1681\/ASN.2014060588","article-title":"Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients.","volume":"26","author":"Halloran","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/ajt.16161","article-title":"Factors associated with kidney graft survival in pure antibody-mediated rejection at the time of indication biopsy: Importance of parenchymal injury but not disease activity.","volume":"21","author":"Einecke","year":"2021","journal-title":"Am J Transplant"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/ajt.15074","article-title":"Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome.","volume":"19","author":"Senev","year":"2019","journal-title":"Am J Transplant"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1097\/TP.0000000000003220","article-title":"Molecular analysis of renal allograft biopsies: Where do we stand and where are we going?","volume":"104","author":"Snijders","year":"2020","journal-title":"Transplantation"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"22220","DOI":"10.1038\/s41598-020-79332-9","article-title":"Molecular patterns of isolated tubulitis differ from tubulitis with interstitial inflammation in early indication biopsies of kidney allografts.","volume":"10","author":"Hruba","year":"2020","journal-title":"Sci Rep"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/tri.13856","article-title":"Three-month course of intragraft transcriptional changes in kidney allografts with early histological minimal injury\u2014a cohort study.","volume":"34","author":"Hruba","year":"2021","journal-title":"Transpl Int"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:18:17Z","timestamp":1749061097000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004284","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,26]]}}}